Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Driessen

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
The British Journal of Dermatology|May 24, 2019
Noninvasive objective skin measurement methods for rosacea assessment: a systematic reviewJ G M Logger, F M C de Vries, P E J van Erp, et al.
Journal of the American Academy of Dermatology|August 1, 2012
Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practicePaula P M van Lümig, Rieke J B Driessen, Wietske Kievit, et al.
The Journal of Dermatological Treatment|May 24, 2007
Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practiceMaartje A M Berends, Rieke J B Driessen, Annechien M G Langewouters, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 26, 2011
Safety of treatment with biologics for psoriasis in daily practice: 5-year dataP P M van Lümig, R J B Driessen, M A M Berends, et al.
Rheumatology (Oxford, England)|December 31, 2009
Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritisRieke J B Driessen, Elke M G J de Jong, Gerrit W Salemink, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologistsHilbert S de Vries, Martijn G H van Oijen, Rieke J B Driessen, et al.
The British Journal of Dermatology|July 24, 2010
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanerceptP P M Van Lümig, L L A Lecluse, R J B Driessen, et al.
Archives of Dermatology|February 17, 2010
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasisLidian L A Lecluse, Rieke J B Driessen, Phyllis I Spuls, et al.
The British Journal of Dermatology|March 25, 2011
Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumabP P M van Lümig, R J B Driessen, M A M A Roelofs-Thijssen, et al.
The British Journal of Dermatology|October 15, 2013
Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasisJ M P A van den Reek, P P M van Lümig, R J B Driessen, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
The British Journal of Dermatology|May 24, 2019
Noninvasive objective skin measurement methods for rosacea assessment: a systematic reviewJ G M Logger, F M C de Vries, P E J van Erp, et al.
Journal of the American Academy of Dermatology|August 1, 2012
Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practicePaula P M van Lümig, Rieke J B Driessen, Wietske Kievit, et al.
The Journal of Dermatological Treatment|May 24, 2007
Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practiceMaartje A M Berends, Rieke J B Driessen, Annechien M G Langewouters, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 26, 2011
Safety of treatment with biologics for psoriasis in daily practice: 5-year dataP P M van Lümig, R J B Driessen, M A M Berends, et al.
Rheumatology (Oxford, England)|December 31, 2009
Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritisRieke J B Driessen, Elke M G J de Jong, Gerrit W Salemink, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologistsHilbert S de Vries, Martijn G H van Oijen, Rieke J B Driessen, et al.
The British Journal of Dermatology|July 24, 2010
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanerceptP P M Van Lümig, L L A Lecluse, R J B Driessen, et al.
Archives of Dermatology|February 17, 2010
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasisLidian L A Lecluse, Rieke J B Driessen, Phyllis I Spuls, et al.
The British Journal of Dermatology|March 25, 2011
Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumabP P M van Lümig, R J B Driessen, M A M A Roelofs-Thijssen, et al.
The British Journal of Dermatology|October 15, 2013
Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasisJ M P A van den Reek, P P M van Lümig, R J B Driessen, et al.
Pageof 10